ERBB2 and gastric cancer: In particular, the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the clinical efficacy of trastuzumab as a first-line regimen for patients with human epidermal growth factor receptor 2 (HER2)-positive unresectable advanced or recurrent gastric cancer [3].